Assetmark Inc. Has $1.15 Million Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Assetmark Inc. boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 5.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 80,982 shares of the company’s stock after purchasing an additional 4,500 shares during the period. Assetmark Inc.’s holdings in Takeda Pharmaceutical were worth $1,152,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $108,000. Envestnet Portfolio Solutions Inc. raised its holdings in Takeda Pharmaceutical by 7.4% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 25,763 shares of the company’s stock worth $358,000 after purchasing an additional 1,778 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Takeda Pharmaceutical by 5.4% in the 1st quarter. SG Americas Securities LLC now owns 16,099 shares of the company’s stock worth $224,000 after purchasing an additional 824 shares during the period. Sei Investments Co. boosted its stake in shares of Takeda Pharmaceutical by 6.7% in the 1st quarter. Sei Investments Co. now owns 372,975 shares of the company’s stock valued at $5,181,000 after purchasing an additional 23,525 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Takeda Pharmaceutical by 65.2% during the first quarter. Russell Investments Group Ltd. now owns 10,676 shares of the company’s stock worth $148,000 after buying an additional 4,213 shares during the period. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Price Performance

TAK stock opened at $13.57 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The firm has a market cap of $43.16 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 0.26 and a beta of 0.54. The company’s fifty day simple moving average is $14.29 and its 200 day simple moving average is $13.82. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.